Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. has demonstrated a strong positive outlook, as evidenced by its raised full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, highlighting robust adoption of its product, DefenCath. The company's fourth-quarter net revenue is anticipated to fall between $115 million and $135 million, which reinforces the momentum toward year-end and reflects greater utilization among outpatient dialysis customers. Additionally, the increased fully synergized pro forma adjusted EBITDA guidance of $220–$240 million further underscores the strong financial performance and operational execution of the company.

Bears say

Cormedix Inc is facing significant challenges related to the uncertainty surrounding the TDAPA pricing, which could negatively impact its financial performance in the near term. Although there is potential for growth through the commercialization of DefenCath and an estimated opportunity valued between $100 million to $200 million, the success of this initiative hinges on overcoming the current pricing headwinds. The company's reliance on a single product and geographic region amplifies these risks, indicating a concerning outlook for its financial stability.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Dec 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.